Explore

Precision Oncology Shifts Towards Integrating Multiple Biomarkers for Treatment Decisions

Precision Oncology Shifts Towards Integrating Multiple Biomarkers for Treatment Decisions

Precision oncology is increasingly moving beyond the reliance on single biomarkers to guide treatment decisions, instead emphasizing the integration of multiple genomic and molecular tests. Experts in a roundtable discussion highlighted that understanding cancer now requires combining diverse sources of molecular information to better comprehend tumor biology and personalize patient care. For instance, in colorectal cancer, the presence of both BRAF V600E mutation and MSI-high status provides two actionable biomarkers, often leading to immunotherapy as the initial treatment. In breast oncology, gene expression assays like Oncotype DX, which evaluate 21 genes, have been used for decades to determine which patients with early-stage ER-positive, HER2-negative breast cancer would benefit from chemotherapy, sparing millions from unnecessary treatments. The discussion also touched upon the complementary roles of protein-based and genomic testing for markers like microsatellite instability and HER2 status, indica...

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics is a specialized field focused on the genomic analysis of tumors to guide cancer treatment decisions. This approach involves studying mutations in oncogenes and tumor suppressor genes, which are critical in the transformation of healthy cells into malignant ones. By understanding these genetic alterations, oncogenomics plays a pivotal role in personalized medicine, allowing for treatments to be tailored to an individual's unique genetic profile. This customization aims to reduce adverse reactions and improve overall healthcare outcomes. The open-access journal Oncotarget actively publishes research across all aspects of oncology, highlighting the ongoing advancements and importance of this field in medical research and practice. Personalized medicine, which includes oncogenomics, has been gaining momentum since the Human Genome Project's completion in 2003, enabling rapid advancements in genetic testing to identify disease-associated mutations.

New Framework Defines Genomic Competencies for Oncology Nurses in Precision Oncology

New Framework Defines Genomic Competencies for Oncology Nurses in Precision Oncology

Researchers have developed the Core Competency Framework for Precision Oncology, a new model designed to define the genomic skills required for oncology nurses and other healthcare professionals. This framework addresses the growing demands on the cancer workforce as genomic technologies, including multigene panels, liquid biopsy, transcriptomics, proteomics, and integrated multi-omic biomarkers, become increasingly integrated into clinical guidelines. The framework, detailed in a report in the journal eClinicalMedicine, was developed through a narrative review of relevant literature and expert consultation. It is structured with three primary components: shared core competencies applicable across professional groups, role-specific competencies tailored to particular functions in precision oncology, and a progression model that outlines increasing levels of complexity, autonomy, and leadership. This adaptable structure aims to support the development of a genomics-capable cancer workforce and facilitate th...

Bionano Genomics Studies Reveal Optical Genome Mapping's Clinical Value in High-Risk Hematologic Malignancies

Bionano Genomics Studies Reveal Optical Genome Mapping's Clinical Value in High-Risk Hematologic Malignancies

Bionano Genomics, Inc. has highlighted three new peer-reviewed studies demonstrating the clinical utility of its optical genome mapping (OGM) technology in high-risk hematologic malignancies. These studies, conducted by independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute, focused on myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and therapy-related myeloid neoplasms (t-MN). The research indicates that OGM can detect prognostically important structural genomic alterations that are often missed by conventional methods such as standard karyotyping, FISH, and targeted sequencing panels. For instance, the MD Anderson study found that OGM identified chromoanagenesis in a significant percentage of MDS cases, correlating with a much shorter median overall survival. The University of Oulu study revealed clinically relevant structural variants in nearly half of cytogenetically normal AML cases, which were associated with...

NRG Oncology Advocate Calls for Enhanced Biomarker Testing and Reduced Treatment Toxicity in Gynecologic Cancer Care

NRG Oncology Advocate Calls for Enhanced Biomarker Testing and Reduced Treatment Toxicity in Gynecologic Cancer Care

Rachel Miller-Garcia, a patient advocate and member of the NRG Oncology Patient Advocate Committee, is urging clinicians to prioritize biomarker testing and circulating tumor DNA (ctDNA) testing as standard of care in gynecologic cancer treatment. She emphasizes that ctDNA testing can determine treatment efficacy or progression months earlier than traditional scanning, potentially reducing unnecessary radiation exposure and debilitating side effects. Miller-Garcia also advocates for addressing treatment toxicity and side effects more proactively in clinical trials, suggesting that lower doses of therapies might be equally effective and more manageable for patients. She highlights significant advancements in treatment, including PARP inhibitors and Antibody Drug Conjugates (ADCs), and the progress in precision medicine through personalized, targeted therapies based on biomarkers and genomic testing. Despite these advances, she notes that side effects from targeted therapies are often underreported in real-w...

New Research Identifies Integrated Biomarkers for Rectal Cancer Treatment Response

New Research Identifies Integrated Biomarkers for Rectal Cancer Treatment Response

A recent study published in Frontiers in Genetics has identified integrated biomarkers that link systemic inflammation and nutrition status to the tumor immune microenvironment, providing insights into neoadjuvant response in locally advanced rectal cancer (LARC). The research focused on the inflammation-nutrition prognostic score (INPS), calculated as the neutrophil-to-lymphocyte ratio (NLR) divided by the prognostic nutritional index (PNI). This score integrates systemic inflammatory burden and nutritional-immunological reserve. The study retrospectively analyzed 312 LARC patients who received standard neoadjuvant chemoradiotherapy, with or without concurrent PD-1/PD-L1 blockade, followed by total mesorectal excision. The findings indicate that a low INPS (<0.058) was significantly associated with a higher objective response rate (61.3% vs. 29.4%) and pathological complete response (38.7% vs. 11.8%). The INPS demonstrated a strong predictive capability for treatment response, outperforming other individu...

BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene, a developer of AI models for tumor and immune biology, has expanded its scientific collaboration with the Dana-Farber Cancer Institute. This expanded partnership aims to deepen the understanding of the complex biological mechanisms driving BRCA1- and BRCA2-associated breast cancers. The collaboration will utilize BostonGene's foundation model of tumor and immune biology and multimodal AI analytics to place individual tumors within a broader biological context. This approach seeks to systematically discover mechanisms that differentiate disease subtypes, drive therapeutic response, and contribute to resistance. The research will focus on BRCA1/2-associated ER-positive breast cancer (BRCA ER+), TP53-mutant ER-positive breast cancer (TP53 ER+), and triple-negative breast cancer (TNBC).

TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug

TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug

TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug

BioNTech's Experimental Drug Gotistobart Shows Significant Survival Benefit in Aggressive Lung Cancer Trial

BioNTech's Experimental Drug Gotistobart Shows Significant Survival Benefit in Aggressive Lung Cancer Trial

BioNTech SE has announced that its experimental drug, gotistobart, nearly doubled the median survival rate for patients suffering from an aggressive form of lung cancer when compared to traditional chemotherapy. The updated results from a late-stage study indicate that patients treated with gotistobart lived for a median of 18.5 months, in contrast to 10 months for those receiving standard-of-care chemotherapy. This trial focused on individuals with metastatic squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy treatments. Earlier data from the study had shown that gotistobart reduced the risk of death by 54%, though median overall survival had not been reached at that point. Rama Balaraman, a principal investigator in the trial and a medical oncologist, highlighted that current survival expectations with established therapies are typically less than a year, and chemotherapy has remained the standard for over a decade in this setting. BioNTech is co...

Guardant360 CDx Liquid Biopsy Test Receives FDA Approval for Early Breast Cancer Treatment Management

Guardant360 CDx Liquid Biopsy Test Receives FDA Approval for Early Breast Cancer Treatment Management

The Guardant360 CDx liquid biopsy test has received FDA approval as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant). This approval is specifically for use in certain advanced breast cancer patients. A significant aspect of this approval is that it marks the first time a test has been sanctioned to guide treatment decisions before a tumor's growth is detectable via traditional scans. Historically, treatment adjustments were typically made only after imaging confirmed tumor progression. This new approval allows for earlier intervention based on liquid biopsy results, potentially changing the paradigm of breast cancer management. The Guardant360 CDx test identifies specific biomarkers in the blood, enabling clinicians to make more timely and targeted therapeutic choices for patients.

New Leukemia Treatment Shows Promise in Preclinical Studies

New Leukemia Treatment Shows Promise in Preclinical Studies

Researchers at the University of Gothenburg and Case Western Reserve University in Cleveland have developed a novel treatment for acute myeloid leukemia (AML). This aggressive form of cancer affects blood and bone marrow, hindering the production of red and white blood cells. The new method, detailed in a study published in Molecular Cancer, involves a molecule named AcTor. AcTor inhibits a signaling protein that influences the mTor protein, which acts as a control center for cell growth and activity. The treatment forces cancer cells to maintain high activity levels while simultaneously shutting down their energy production in the mitochondria, leading to their demise from stress. This approach is unique because it does not harm healthy blood cells and appears to prevent drug resistance, a common issue in cancer treatments. The study demonstrated a strong effect on leukemia in AML cell lines, primary patient samples, and animal trials, particularly when combined with the inhibitor Ixazomib (IXZ). Notably,...

Tempus AI Launches Initiative to Build Largest Multimodal Whole-Genome Dataset for AI-Driven Healthcare

Tempus AI Launches Initiative to Build Largest Multimodal Whole-Genome Dataset for AI-Driven Healthcare

Tempus AI, Inc. (NASDAQ: TEM) has announced a new initiative to create a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. This effort aims to establish the first de-identified multimodal whole-genome sequencing (WGS) dataset specifically optimized for AI-driven research, built around disease populations and patient outcomes. Following the completion of this initial dataset, Tempus plans to expand the project with a long-term goal of reaching one million genomes. Unlike existing population-scale genome programs that primarily draw from general populations, Tempus's dataset will integrate genomic data with longitudinal disease and treatment outcomes. The company has already developed one of the largest multimodal real-world oncology databases, which has been used to inform drug development decisions. This new WGS dataset will be incorporated into Tempus’ existing de-identified multimodal data environment, allowing researchers to acces...